202 related articles for article (PubMed ID: 35269515)
1. Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery.
Boeckmans J; Gatzios A; Heymans A; Rombaut M; Rogiers V; De Kock J; Vanhaecke T; Rodrigues RM
Cells; 2022 Mar; 11(5):. PubMed ID: 35269515
[TBL] [Abstract][Full Text] [Related]
2. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
3. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH.
Boeckmans J; Buyl K; Natale A; Vandenbempt V; Branson S; De Boe V; Rogiers V; De Kock J; Rodrigues RM; Vanhaecke T
Pharmacol Res; 2019 Jun; 144():377-389. PubMed ID: 31028903
[TBL] [Abstract][Full Text] [Related]
4. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
[No Abstract] [Full Text] [Related]
5. Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.
Boeckmans J; Natale A; Rombaut M; Buyl K; Cami B; De Boe V; Heymans A; Rogiers V; De Kock J; Vanhaecke T; Rodrigues RM
Cell Biol Toxicol; 2021 Apr; 37(2):293-311. PubMed ID: 32613381
[TBL] [Abstract][Full Text] [Related]
6. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
Briand F; Maupoint J; Brousseau E; Breyner N; Bouchet M; Costard C; Leste-Lasserre T; Petitjean M; Chen L; Chabrat A; Richard V; Burcelin R; Dubroca C; Sulpice T
Metabolism; 2021 Apr; 117():154707. PubMed ID: 33444606
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.
van den Hoek AM; Verschuren L; Caspers MPM; Worms N; Menke AL; Princen HMG
Sci Rep; 2021 Mar; 11(1):5050. PubMed ID: 33658534
[TBL] [Abstract][Full Text] [Related]
8. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomics data of a human
Boeckmans J; Buyl K; Natale A; Vandenbempt V; Branson S; De Boe V; Rogiers V; De Kock J; Rodrigues RM; Vanhaecke T
Data Brief; 2019 Aug; 25():104093. PubMed ID: 31294056
[TBL] [Abstract][Full Text] [Related]
10. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
[TBL] [Abstract][Full Text] [Related]
11. Investigating fibrosis and inflammation in an ex vivo NASH murine model.
Gore E; Bigaeva E; Oldenburger A; Jansen YJM; Schuppan D; Boersema M; Rippmann JF; Broermann A; Olinga P
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G336-G351. PubMed ID: 31905025
[TBL] [Abstract][Full Text] [Related]
12. Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice.
Tsai HC; Chang FP; Li TH; Liu CW; Huang CC; Huang SF; Yang YY; Lee KC; Hsieh YC; Wang YW; Lee TY; Huang YH; Hou MC; Lin HC
Biomed Res Int; 2019; 2019():6740616. PubMed ID: 31321239
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis.
Malik A; Nadeem M; Malik MI
Clin J Gastroenterol; 2021 Dec; 14(6):1579-1586. PubMed ID: 34370218
[TBL] [Abstract][Full Text] [Related]
14. Elafibranor interrupts adipose dysfunction-mediated gut and liver injury in mice with alcoholic steatohepatitis.
Li TH; Yang YY; Huang CC; Liu CW; Tsai HC; Lin MW; Tsai CY; Huang SF; Wang YW; Lee TY; Huang YH; Hou MC; Lin HC
Clin Sci (Lond); 2019 Feb; 133(3):531-544. PubMed ID: 30602573
[No Abstract] [Full Text] [Related]
15. Elafibranor modulates ileal macrophage polarization to restore intestinal integrity in NASH: Potential crosstalk between ileal IL-10/STAT3 and hepatic TLR4/NF-κB axes.
Hakeem AN; Kamal MM; Tawfiq RA; Abdelrahman BA; Hammam OA; Elmazar MM; El-Khatib AS; Attia YM
Biomed Pharmacother; 2023 Jan; 157():114050. PubMed ID: 36462310
[TBL] [Abstract][Full Text] [Related]
16. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
17. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.
Perakakis N; Stefanakis K; Feigh M; Veidal SS; Mantzoros CS
Liver Int; 2021 Aug; 41(8):1853-1866. PubMed ID: 33788377
[TBL] [Abstract][Full Text] [Related]
18. The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.
Liu L; Liu C; Zhao M; Zhang Q; Lu Y; Liu P; Yang H; Yang J; Chen X; Yao Y
PLoS One; 2020; 15(12):e0243911. PubMed ID: 33326461
[TBL] [Abstract][Full Text] [Related]
19. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
20. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
Roth JD; Veidal SS; Fensholdt LKD; Rigbolt KTG; Papazyan R; Nielsen JC; Feigh M; Vrang N; Young M; Jelsing J; Adorini L; Hansen HH
Sci Rep; 2019 Jun; 9(1):9046. PubMed ID: 31227742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
